| Document |
Document Title |
|
WO/2000/001676A1 |
This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation...
|
|
WO1999058500B1 |
The invention relates to a method for stereochemically controlled production of azacyclic compounds of general formula (I), whereby the substituents have the meaning cited in the description. The invention also relates to intermediate pr...
|
|
WO/1999/066005A1 |
Chemiluminescent labeling compounds and chemiluminescent labeled conjugates are provided. The compounds comprise an acridan ring bearing an exocyclic double bond and further contain a labeling substituent which permits attachement to com...
|
|
WO/1999/057221A1 |
A highly durable organic EL element which luminesces at a sufficient brightness especially at long wavelengths and retains the satisfactory luminescent performance over long; and compounds for use in producing the element. The compounds ...
|
|
WO/1999/057220A1 |
Compounds for organic EL devices exhibiting electroluminescence satisfactory in luminance, particularly a long-wavelength one, and being so excellent in durability that the good luminescence performances can last over a long period; and ...
|
|
WO1998003497A9 |
Compounds, constructed in modular manner, of formula (I), wherein I is the monovalent residue of an ionophore, F is the monovalent residue of a fluorophore, G is a functional group, T is a trivalent organic radical and R01, R02 and R03 a...
|
|
WO/1999/048492A1 |
Compounds represented by general formula (1') and nociceptin antagonists containing the compounds [1'] as the active ingredient wherein R?2¿ represents optionally hydroxylated lower alkyl, amino, etc.; the ring B represents phenyl, thie...
|
|
WO/1999/034915A1 |
Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition, while substantially maintaining a desired biological activity of the biological composition. The device compri...
|
|
WO/1999/034914A1 |
Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition containing cells while substantially maintaining a desired biological activity of the biological composition. T...
|
|
WO/1999/014220A1 |
Novel compounds comprising a C-C double bond substituted at one carbon with two oxygen or sulfur atom-containing groups are disclosed. The compounds are useful in methods and compositions for generating chemiluminescence by reaction with...
|
|
WO/1999/009012A1 |
A compound is provided having formula (I), where C* is an sp2 co-ordinated carbon atom; A is a 9-acridinyl or substituted 9-acridinyl moiety; Z is a moiety that is covalently bonded to C* including, but not limited to O, S, N-R?1¿ or ?+...
|
|
WO/1999/007683A1 |
The invention relates to a novel process for producing 3,6-diaminoacridine or its hydrochloride. The inventive processes enable these substances to be produced with a high degree of purity.
|
|
WO/1999/006372A1 |
The present invention relates to bis-acridinecarboxamides and the derivatives thereof substituted with aminoalkyl chains, have evidenced a remarkable antitumor activity, in particular in colon tumors.
|
|
WO/1999/005521A2 |
The invention relates to conjugates, comprising a fluorescent compound and a carrier, wherein the compound and the carrier are connected via an acidic ester or an acidic amide bond and the compound has an excitation wavelength of 630 nm ...
|
|
WO/1999/003823A2 |
Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is d...
|
|
WO/1998/057956A1 |
A series of bis-acridinyl DNA intercalating agents with anticancer cell activity represented by formula (I), where Z is a linear arrangement of multiple aromatic rings, containing at least three aromatic rings, or at least two alicyclic ...
|
|
WO/1998/056765A1 |
The invention concerns chemoluminescent acridinium derivatives of formula (I) in which R�1? to R�13? are substituents not hindering the expression of chemoluminescence, provided that at least one of the substituents R�12? and R�1...
|
|
WO/1998/054148A2 |
Compounds having formula (I) or (II) where R is primary or secondary amine or a group -L-Z, Y is H, halogen, alkyl, alkoxy, perfluoroalkyl, nitro or -L-Z, n is 1 to 4, L is a linker chain of 1-20 C, N, O or S atoms, and Z is a calcium ch...
|
|
WO/1998/049146A2 |
Certain derivatives of acridones and benzothiadiazines have been found to have anti-cancer properties by virtue of their specific inhibition of the cyclin D dependant kinase CDK4. These molecules inhibit CDK4 activity more than they inhi...
|
|
WO/1998/042655A1 |
The invention relates to spiro compounds of the formula (I) wherein at least one of the radicals K?1�, L, M, N?1�, R?1�, R?2�, R?3�, R?4� is one of the groups (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) and (k). Said spi...
|
|
WO/1998/030545A1 |
Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods ...
|
|
WO/1998/030327A1 |
Methods and devices for reducing the concentration of small organic compounds in a blood product while substantially maintaining a desired biological activity of the blood product, the device comprising highly porous adsorbent particles,...
|
|
WO/1998/030218A1 |
This invention relates to substituted bis-acridines and related compounds which are ligands, in particular, antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated...
|
|
WO/1998/030544A1 |
The invention concerns new compouds of formula (1) wherein R=H or CH�3? and of formula (2) wherein R=H or CH�3?, HX represents an acid, n is 1 or 2. The compounds possess antimicrobial activity.
|
|
WO/1998/029399A1 |
The invention relates to ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention includes an anionic portion combined with at least one cationic portion M?+m� in sufficient numbers to ensur...
|
|
WO/1998/029388A1 |
The invention relates to ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention is comprised of an amide or one of its salts, including an anionic portion combined with at least one cationic...
|
|
WO/1998/029877A1 |
Disclosed is a proton conductor in liquid form, comprised of a mixture of the following components: (a) a salt combined with a nitrogenated base along with an acid, according to formula (I), wherein Z�1?, Z�2?, Z�3?, and Z�4?, wh...
|
|
WO/1998/029389A1 |
The invention is related to ionic compounds, derivatives of malononitrile, in which the anionic load has been displaced. An ionic compound disclosed by the invention includes an anionic portion combined with at least one cationic portion...
|
|
WO/1998/029396A1 |
The invention relates to ionic compounds in which the anionic load has been displaced, and the uses of these compounds. A compound disclosed by the invention comprises an anionic portion combined with at least one cationic portion M?+mï¿...
|
|
WO/1998/029358A2 |
Disclosed is a method for grafting a polymer onto the surface of a carbonate material with carboxyl, amine, and/or hydroxyl functions on its surface. Said material is placed in suspension in a solution including the polymer to be grafted...
|
|
WO/1998/027101A1 |
The present invention relates to the production of novel catalysts made from transition metal compounds and 'three-toothed' 4,5-diphosphinoacridine-ligands ('Acriphos'). The ligands used to this effect are diphosphine compounds of 4,5-di...
|
|
WO/1998/025615A1 |
This invention provides methods for the treatment or inhibition of oral squamous cell carcinoma which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B�4? antagonist.
|
|
WO/1998/025616A1 |
This invention provides methods for the treatment or prevention of cerebral focal ischemia which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B�4? antagonist.
|
|
WO/1998/023589A1 |
A process of converting a hydroxy heteroaromatic compound to an arylamine, comprising the steps of : 1) treating a salt of a hydroxy heteroaromatic compound with an alkylating agent; and 2) treating the reaction mixture with a Smiles sol...
|
|
WO/1998/021586A1 |
Methods of detecting analytes or target species using two enzyme-labeled specific binding partners where the two enzymes function in concert to produce a detectable chemiluminescent signal are disclosed. The methods use a specific bindin...
|
|
WO/1998/017826A1 |
The present invention relates to genetic mutations in mitochondrial genes that segregate with diabetes mellitus. The invention provides methods for detecting such mutations, as a diagnostic for diabetes mellitus, either before or after t...
|
|
WO/1998/017649A1 |
A process for producing an acridine carboxamide of formula (I) wherein each of R?1�, R?2�, R?5� and R?6�, which may be the same or different, is hydrogen or an organic substituent, x is an integer of 1 to 6 and Y is N(R)�2? whe...
|
|
WO/1998/017650A1 |
A compound which is a bis(acridinecarboxamide) or bis(phenazinecarboxamide) derivative of formula (I), wherein each X, which may be the same or different in a given molecule, is -CH= or -N= each of R�1? to R�4? which may be the same ...
|
|
WO/1998/013352A1 |
The present invention relates to biologically active synthetic compounds related to the class of aminoglucose derivatives. This invention more precisely relates to 2-deoxy-2-amino(or 2-methylamino)-D-glucose salts that comprise N-arachid...
|
|
WO/1998/007844A2 |
A cell-based assay technique for identifying and evaluating chemical compounds and agents which affect the production of Pth-rP in mammalian cells and other cell types is set forth. Specifically , tumor cell lines are transformed with an...
|
|
WO/1998/003474A1 |
The invention concerns novel glyoxylic acid derivatives, a process for their preparation and their use as pesticides.
|
|
WO/1998/002421A1 |
New dibenzodihydropyridinecarboxylic esters are provided which comply with formula (1) or (2), wherein: R?1� is substituted alkyl or cyano; R?2� and R?3� are independently hydrogen, alkyl, substituted alkyl, aryl or substituted ary...
|
|
WO/1997/040014A1 |
Fluoroionophores of formula (I) wherein R06 is H or substituted or unsubstituted C1-C20alkyl, R6 is H or substituted or unsubstituted C1-C30alkyl or C1-C30alkoxy, R1 is a bridging group, and F is a residue of a fluorophore. The fluoroion...
|
|
WO/1997/039337A1 |
Fluoroionophores that are functionalised with reactive groups and correspond to the formula I-R1-F-R2-G, wherein I is a monovalent residue of an ionophore, wherein F is a divalent residue of a fluorophore, wherein G is a functional group...
|
|
WO/1997/038999A1 |
The present invention relates to several novel acridone-derived compounds of formula (I) or (II). These compounds are potent anti-viral agents, useful in the treatment of viral diseases, such as Human Immunodeficiency Virus. In addition,...
|
|
WO/1997/027179A2 |
The invention relates to the use of a compound of formula (I), wherein R1 and R2 are independently amino, N-alkylamino, N,N-dialkylamino, cycloalkylamino, amidino, N-lower alkylamidino, N,N-di-lower alkylamidino, guanidino, N-lower alkyl...
|
|
WO/1997/026245A1 |
Novel heterocyclic compounds which generate chemiluminescence on reaction with a phosphatase enzyme are provided as well as a process for their preparation and intermediates useful therein. The compounds comprise a nitrogen, oxygen or su...
|
|
WO/1997/021681A1 |
The present invention provides cholinesterase inhibitors of general formula (I) wherein R is H or (C1-C4)alkyl, Y is a linking group and Z is an alkyl or aryl group, including heteroaryl groups, and the pharmaceutically acceptable salts ...
|
|
WO/1997/019929A1 |
Compounds of Formula (I), methods for their preparation, pharmaceutical formulations and use thereof.
|
|
WO/1997/019054A1 |
The present invention relates to chromotropic nitrone spin trapping agents, methods of making these agents, compositions comprising same, and methods of their use. In particular, azulenyl nitrones of the present invention are effective a...
|
